885 related articles for article (PubMed ID: 16942032)
1. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
2. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
[TBL] [Abstract][Full Text] [Related]
3. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists.
Ali SM; Tedford CE; Gregory R; Handley MK; Yates SL; Hirth WW; Phillips JG
J Med Chem; 1999 Mar; 42(5):903-9. PubMed ID: 10072687
[TBL] [Abstract][Full Text] [Related]
5. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
6. Development of versatile cis- and trans-dicarbon-substituted chiral cyclopropane units: synthesis of (1S,2R)- and (1R,2R)-2-aminomethyl-1-(1H-imidazol-4-yl)cyclopropanes and their enantiomers as conformationally restricted analogues of histamine.
Kazuta Y; Matsuda A; Shuto S
J Org Chem; 2002 Mar; 67(5):1669-77. PubMed ID: 11871901
[TBL] [Abstract][Full Text] [Related]
7. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the bioactive conformation of histamine H3 receptor antagonists by the cyclopropylic strain-based conformational restriction strategy.
Watanabe M; Hirokawa T; Kobayashi T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
J Med Chem; 2010 May; 53(9):3585-93. PubMed ID: 20397706
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.
De Esch IJ; Vollinga RC; Goubitz K; Schenk H; Appelberg U; Hacksell U; Lemstra S; Zuiderveld OP; Hoffmann M; Leurs R; Menge WM; Timmerman H
J Med Chem; 1999 Apr; 42(7):1115-22. PubMed ID: 10197956
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structural and pharmacological properties of cyclopropane-based conformationally restricted analogs of 4-methylhistamine as histamine H3/H4 receptor ligands.
Kobayashi T; Watanabe M; Yoshida A; Yamada S; Ito M; Abe H; Ito Y; Arisawa M; Shuto S
Bioorg Med Chem; 2010 Feb; 18(3):1076-82. PubMed ID: 20045649
[TBL] [Abstract][Full Text] [Related]
13. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
[TBL] [Abstract][Full Text] [Related]
14. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
[TBL] [Abstract][Full Text] [Related]
15. Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates.
Łazewska D; Wiecek M; Ligneau X; Kottke T; Weizel L; Seifert R; Schunack W; Stark H; Kieć-Kononowicz K
Bioorg Med Chem Lett; 2009 Dec; 19(23):6682-5. PubMed ID: 19846299
[TBL] [Abstract][Full Text] [Related]
16. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
[TBL] [Abstract][Full Text] [Related]
17. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
18. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
Hashimoto T; Harusawa S; Araki L; Zuiderveld OP; Smit MJ; Imazu T; Takashima S; Yamamoto Y; Sakamoto Y; Kurihara T; Leurs R; Bakker RA; Yamatodani A
J Med Chem; 2003 Jul; 46(14):3162-5. PubMed ID: 12825954
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.
Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y
J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643
[TBL] [Abstract][Full Text] [Related]
20. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
